Recruitment of both Tc1 and γδ T17 cells in CT26 and TS/A tumors that correlate with better tumor control. (A–C) CT26 colon cancer treated with anthracyclines. (A) Tumor size before and 8 d after treatment with PBS (filled symbols) or DX (open symbols). (B) The percentage of CD8⁺ T cells among CD3⁺ cells and of IFN-γ–producing cells among CD8⁺ T cells. (C) The percentage of γδ T cells among CD3⁺ cells and of IL-17A–producing cells among CD3⁺ γδ T cells. Data are presented as mean ± SEM with five tumors/group. (D–F) TS/A mammary cancer treated with x rays. (D) Established TS/A tumors were treated with local irradiation (open symbols) on day 10. Mice were segregated into nonresponders (tumor progression [TP], triangles) and responders (tumor regression [TR], circles) 22 d after radiotherapy (n = 5). (E) The percentage of CD8⁺ T cells among CD3⁺ cells and of IFN-γ-producing cells among CD8⁺ T cells; (F) The percentage of γδ T cells among CD3⁺ cells and of IL-17A–producing cells among CD3⁺ γδ T cells are indicated as mean ± SEM. (G) The correlation between the percentages of γδ T17 and Tc1 TILs in all tumors (treated or not) was plotted for MCA205, CT26, and TS/A tumors (each dot representing one mouse). Data are representative of two to three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.